T

he Seattle biotech Omeros (OMER) lost favorable Medicare reimbursement for its only approved product — a cataract surgery drug — at the end of last year, making it likely sales will plunge this year, according to a consultant to the company.

The favorable policy meant hospitals and surgery centers where Medicare patients go for cataract procedures received a separate reimbursement for the drug, Omidria, for three years. But that policy expired when the calendar clicked over to Jan. 1, said Kevin Corcoran, president of Corcoran Consulting Group and an expert on ophthalmology reimbursement issues. Omeros is a Corcoran client.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.